Author

S. D. Gore

Observed names: S D Gore, S. Gore, SD Gore, Steve Gore

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center

Observed institutions: Louisiana State University, University of Maryland, Baltimore, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Johns Hopkins Medicine, University of Florida, University of Kansas Medical Center, Johns Hopkins Hospital, Sidney Kimmel Comprehensive Cancer Center, Louisiana State University Health Sciences Center New Orleans

OpenAlex ID: A5111892402

A phase 2 study of vorinostat in acute myeloid leukemia

2009 · E. W. Schaefer, A. Loaiza-Bonilla, et al. · Haematologica · 120

Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography

2004 · Ming Zhao, Michelle A. Rudek, et al. · Journal of Chromatography B · 42

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

2011 · S. W. Smith, M. Sato, et al. · Haematologica · 40

Steel factor supports the cycling of isolated human CD34+ cells in the absence of other growth factors.

1995 · S D Gore, S Amin, et al. · PubMed · 37

Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all-trans retinoic acid

1999 · KH Yu, L-J Weng, et al. · Leukemia · 35

Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults

2012 · D. P. Zandberg, T.-Y. Huang, et al. · Haematologica · 16

Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes

2011 · A. J. Davidoff, S. Weiss Smith, et al. · Haematologica · 14

Pharmacokinetics of 5-azacitidine given with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies

2005 · M. A. Rudek, M. Zhao, et al. · Journal of Clinical Oncology · 2

Relationship of progression to acute myeloid leukemia (AML) from myelodysplastic syndrome (MDS) and cytogenetic status

2008 · E. Hellstrom-Lindberg, P. Fenaux, et al. · Journal of Clinical Oncology · 1

The pharmacokinetics of azacitidine following subcutaneous treatment in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML)

2009 · E. Laille, R. Ward, et al. · Journal of Clinical Oncology

Works count: 10

Citation count: 307

H-index: 7

I10-index: 7